Table 1 Patient cohorts used in study.
From: Development and validation of a circulating microRNA panel for the early detection of breast cancer
Cohort: | Discovery | Validation 1 | Validation 2 | |||||
|---|---|---|---|---|---|---|---|---|
Non-cancer (NC)/Cancer (C): | NC | C | NC | C | NC | C | ||
106 | 183 | 197 | 177 | 199 | 180 | |||
Source | Ethnicity | |||||||
1 | Asterand biobank (Europe) | Caucasian | 106 (100%) | 183 (100%) | – | – | – | – |
2 | Asterand biobank (USA) | Caucasian | – | – | 39 (19%) | 39 (22%) | 39 (19%) | 40 (22%) |
3 | Tissue Solutions biobank (Ukraine) | Caucasian | – | – | 33 (17%) | 23 (13%) | 34 (17%) | 24 (13%) |
4 | Tissue Solutions biobank (Russia) | Caucasian | – | – | 47 (24%) | 48 (27%) | 47 (24%) | 48 (27%) |
5 | National University Hospital | Asian (Singapore) | – | – | 35 (18%) | 38 (21%) | 35 (18%) | 38 (21%) |
6 | National Cancer Centre Singapore | Asian (Singapore) | – | – | 43 (22%) | 29 (16%) | 44 (22%) | 30 (17%) |
Age (years) | ||||||||
Mean | 53.7 | 52.4 | 53.0 | 56.6 | 55.5 | 55.4 | ||
Median | 53 | 51 | 52 | 57 | 56 | 55 | ||
Range | 42–65 | 30–85 | 29–82 | 31–77 | 26–83 | 28–87 | ||
Sex | ||||||||
Male | 0 | 0 | 0 | 0 | 0 | 0 | ||
Female | 106 | 183 | 197 | 177 | 199 | 180 | ||
Cancer Stage | ||||||||
0 | – | 0 (0%) | – | 16 (9%) | – | 23 (13%) | ||
I | – | 77 (42%) | – | 51 (29%) | – | 45 (25%) | ||
II | – | 78 (43%) | – | 61 (34%) | – | 58 (32%) | ||
III | – | 28 (15%) | – | 5 (3%) | – | 8 (4%) | ||
IV | – | 0 (0%) | – | 3 (2%) | – | 3 (2%) | ||
Unknown | – | 0 (0%) | – | 41 (23%) | – | 43 (24%) |
